Endoluminal & Bronchoscopy Robots Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is endoluminal and bronchoscopy robots market size?

USD 938.0 million in 2026 and USD 8736.0 million by 2036 at a 25.0% CAGR.

Demand for endoluminal and bronchoscopy robots is projected to expand at 25.0% CAGR between 2026 and 2036, increasing valuation from USD 938.0 million in 2026 to USD 8736.0 million by 2036. Modern hospitals increasingly adopt robotic lung biopsy, a robotic technology to improve lung diagnostics and bronchoscopy procedures. An Intuitive Surgical quarterly filing issued in April 2026 recorded approximately 42,700 Ion procedures during first-quarter 2026. An impressive procedure volume indicates sustained utilization across established robotic lung biopsy programs.

Regional healthcare priorities heavily influence how medical networks expand their endoluminal surgical capacities. United States and European hospital groups prioritize published yield evidence and specialist education during platform evaluations. China and India care networks value regional service capacity and flexible placement structures. An Intuitive Surgical filing issued in April 2026 documented 52 Ion placements during first-quarter 2026. Such consistent equipment installations point to continued capacity additions across global endoluminal programs.

Summary of Endoluminal & Bronchoscopy Robots Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Endoluminal and bronchoscopy robot selection advances as hospitals connect diagnostic confidence with coordinated oncology care. Program decisions reflect published clinical evidence and specialist education across multidisciplinary hospital services. Interventional pulmonology teams seek controlled access to peripheral lung nodules using stable robotic biopsy devices and catheter positioning. Gastroenterology programs assess flexible robotic platforms beside established resection workflows using disposable endoscopes for selected procedures. Hospital committees value multicenter evidence recording lesion access and diagnostic performance across varied clinical sites. Thoracic oncology services benefit from coordinated biopsy planning intended to shorten movement from diagnosis into treatment pathways. Specialist education access is anticipated to influence utilization and procedural confidence across participating departments.
Product and Segment View	Segment direction is led by robotic bronchoscopy, followed by lung nodule biopsy and systems across established programs. Specification review is expected to center on navigation precision and procedural integration across specialty teams. Robotic bronchoscopy is predicted to garner 56.0% share in 2026 owing to established lung-biopsy platforms and trained pulmonology teams. Lung nodule biopsy is anticipated to hold 52.0% share in 2026, led by screening-linked diagnostic needs across thoracic oncology services. Systems are likely to secure 46.0% share in 2026, driven by continued capital-platform placements across established hospital programs.
Geography and Growth Outlook	Country movement differs through hospital investment capacity and specialist availability across regional care networks. Company progress reflects local education access and clinical program depth across referral centers and university hospitals. China is forecast to expand at 28.0% CAGR by 2036, backed by tertiary-care expansion across provincial centers. European Union demand is predicted to rise at 26.0% CAGR during forecast period, aided by coordinated oncology networks and university hospitals. United States sales are estimated to record 24.0% CAGR from 2026 to 2036, guided by established platform access and clinician education.
Competitive View	Competition centers on navigation performance and clinical workflow support across interventional pulmonology and gastroenterology programs. Commercial progress favors companies offering procedural education and dependable field service across participating hospital networks. Intuitive Surgical and Johnson & Johnson MedTech are expected to compete based on established bronchoscopy platforms and procedural education. Noah Medical is projected to support imaging-led evaluation across peripheral lung nodule procedures requiring real-time lesion confirmation. EndoQuest Robotics is anticipated to receive review across investigational therapeutic endoluminal applications involving flexible instrument access.
Analyst Perspective	Endoluminal robotics supports procedural planning for lesions requiring controlled access and coordinated tissue sampling during biopsy. Company progress is expected to improve through measured evidence and specialist-led education across participating clinical services. Clinical leaders assess platform utility through lesion access and diagnostic performance across complete procedures involving difficult pulmonary targets. Hospital teams value systems supporting pulmonology workflows without disrupting imaging or pathology coordination across multidisciplinary oncology services. Regional education access improves confidence during expansion across several clinical sites and newly trained specialist groups. - Anurag Sharma, Principal Consultant for Healthcare at Future Market Insights

Source: Future Market Insights analysis, 2026.

How is endoluminal and bronchoscopy robots market segmented?

The endoluminal and bronchoscopy robots industry is segmented by platform, application, component, end user, business model, and region.

The endoluminal and bronchoscopy robots market is segmented by platform, application, component, end user, business model, and region. Platform coverage includes robotic bronchoscopy and robotic GI endoscopy followed by urology endoluminal systems and others. Application coverage addresses lung nodule biopsy and GI lesion resection with kidney stone intervention and other procedures. Component coverage encompasses systems and catheters & scopes supported by installation and continuing clinical services. End-user coverage spans academic hospitals and community hospitals with cancer centers offering specialist diagnostic programs. Business-model coverage includes capital purchase and per-procedure consumables through lease arrangements and placement programs. Regional coverage includes North America and Europe together with Asia Pacific. Latin America and Middle East and Africa complete geographic analysis across developing hospital systems.

Why does robotic bronchoscopy shape platform selection?

Zhang and colleagues reported in January 2024 a pooled robotic bronchoscopy diagnostic yield of 80.4%, impacting platform review for peripheral pulmonary lesion procedures requiring controlled reach. This clinical performance directs hospital attention toward navigation software and articulating catheters guiding clinicians along planned airway paths toward difficult nodules. Robotic gastrointestinal endoscopy extends the same minimally invasive principle into therapeutic digestive procedures requiring precise tissue access and controlled instrument movement.

• Robotic bronchoscopy is set to represent 56.0% share of platform revenue in 2026, backed by established clinical use across lung nodule diagnosis. Hospital teams assess navigation stability and lesion confirmation across complete procedures to evaluate performance beyond initial access.
• Robotic gastrointestinal endoscopy and urology endoluminal systems address therapeutic work involving flexible access based on natural openings. Procedure planning considers instrument reach and tissue control during carefully selected investigational cases.

How does lung nodule biopsy shape application demand?

Screening and imaging programs identify small nodules that frequently require tissue confirmation before clinicians can select an appropriate oncology pathway. It supports lung nodule biopsy as the principal application, and gastrointestinal lesion resection applies comparable robotic precision to therapeutic procedures across the digestive tract. World Health Organization reported in July 2026 approximately 2.6 million lung cancer cases worldwide during 2024, reinforcing diagnostic needs for precise access to suspicious peripheral lesions.

• Based on application, lung nodule biopsy is anticipated to secure 52.0% share in 2026 owing to established bronchoscopy platforms and expanding screening-linked referrals. Pulmonology teams examine lesion reach and tissue adequacy driven by endobronchial ultrasound biopsy pathways prior to adopting robotic support.
• Gastrointestinal lesion resection and kidney stone intervention create distinct procedural needs involving flexible access and precise instrument control. Lesion location and required instrument motion guide case assignment among participating specialist services.

Why do systems account for component leadership?

Intuitive Surgical reported in January 2026 an installed base of 995 Ion systems at year-end 2025, documenting continued capital-platform expansion across bronchoscopy programs. Each installed system combines robotic drive units and imaging integration to support planning and instrument guidance during procedures. Catheters and scopes operate within this system architecture as recurring procedural components, linking capital-equipment use with continuing supply and service requirements.

• By component, systems are forecast to garner 46.0% share in 2026 as platform value reflects robotic controls and navigation equipment. Hospital committees compare clinical workflow integration and service response through an endoscopy visualization system already used across interventional suites.
• Catheters and scopes support repeated procedural access through sterile or reprocessed instrument pathways across scheduled clinical cases. Procedure teams pair cytology brushes with service support selected for specimen collection and equipment readiness.

Why do academic hospitals lead end-user demand?

Johnson & Johnson MedTech reported in May 2025 a TARGET study spanning 21 global sites, illustrating academic and tertiary-center participation in robotic bronchoscopy evidence development. Such institutions combine thoracic surgery and advanced imaging expertise within coordinated programs supporting research and complex procedures. Leading community hospitals and cancer centers to extend access by managing referred cases as specialist training and procedural pathways become established.

• Academic hospitals are projected to hold 44.0% share in 2026, guided by clinical-study participation and specialist education infrastructure. Research teams evaluate platform performance across defined protocols involving biopsy guidance system support and pathology confirmation.
• Community hospitals and cancer centers extend access through regional oncology networks serving referred patients across several communities. Referral volume and clinician availability shape scheduling plans within regional oncology services.

How does capital purchase retain business model strength?

Capital purchase gives established hospitals direct control over equipment availability and operating schedules. Placement programs provide an alternative for developing services by connecting initial system access with recurring procedural inputs during gradual volume expansion. An Intuitive Surgical annual filing issued in February 2026 recorded 49% of Ion placements under operating leases during 2025, revealing material use of flexible access structures beside ownership.

• In 2026, capital purchase is estimated to hold 44.0% share since it is helped by hospital control over system availability and operating schedules. Organizations connect ownership with trained specialists and documented maintenance routines across established interventional programs serving scheduled patients.
• Per-procedure consumables and leases distribute payment across procedural activity without full ownership during system installation. Site committees review expected case flow and payment exposure during each staged evaluation.

What are drivers, restraints, and opportunities in endoluminal and bronchoscopy robots market?

Screening-linked diagnostic needs and clinical evidence support robotic platform evaluation. Capital intensity and specialist requirements may delay routine use across lower-volume hospitals.

• Driver: Pulmonology teams need controlled peripheral lesion access for dependable tissue diagnosis across oncology pathways. Multidisciplinary services favor tools supporting accurate sampling and coordinated treatment planning for referred patients entering specialist care.
• Restraint: High initial platform expense may challenge lower-volume hospitals lacking consistent procedure throughput across specialist services. Specialist education needs may extend implementation across new clinical teams during early procedural use and supervised case preparation.
• Opportunity: Therapeutic gastrointestinal and urology programs may extend procedural utility beyond lung biopsy into natural-opening surgery. Flexible service structures are expected to improve access across developing hospital networks establishing specialty programs.

American Cancer Society researchers reported in November 2025 screening participation of 18.7% among eligible United States adults during 2024, revealing substantial referral headroom for small-nodule workups. Diagnostic pathways are projected to combine lung biopsy systems with robotic navigation for difficult peripheral targets. Expanding screening access is expected to increase referrals for robotic assessment of peripheral lung nodules.

Capital exposure remains a constraint for hospitals building early robotic bronchoscopy volume across lower-throughput clinical services. An Intuitive Surgical annual filing submitted in January 2025 documented 153 Ion systems placed under operating leases during 2024, illustrating demand for structures reducing immediate ownership burden. Community hospitals are likely to favor staged access during early service development and specialist education.

Therapeutic procedures offer an opportunity for multi-specialty platform expansion beyond pulmonology into gastrointestinal treatment programs. National Cancer Institute figures updated in May 2025 estimated 107,320 United States colon cancer cases for 2025, supporting clinical needs for advanced colorectal diagnosis and oncology resection devices. Specialist evidence is anticipated to guide evaluation across gastrointestinal programs reviewing flexible robotic instruments for therapeutic procedures.

How are country CAGRs aligned in endoluminal and bronchoscopy robots market?

Country or Market	CAGR
China	28.0%
European Union	26.0%
United States	24.0%
Japan	23.0%
India	22.0%

Source: Future Market Insights analysis, 2026.

How do country-level CAGRs compare in endoluminal and bronchoscopy robots market?

Country comparison shows a gradual step-down in growth across the markets covered. China sits at the upper end of the range, followed by the European Union. United States and Japan form a closely grouped middle tier. India remains at the lower end of the comparison. The six-point spread shows that these markets share a strong growth outlook, although their relative positions indicate different levels of market momentum. European Union figure represents a regional average, so individual member countries may record higher or lower growth.

• China leads the comparison and establishes East Asia as a notable growth cluster among the markets shown.
• European Union follows China and maintains a relatively small gap from the leading market.
• United States and Japan form the next growth band, which indicates that neither market falls far behind the upper group.
• India records the slowest growth among the listed markets, yet its forecast remains strong within the wider market context.
• The pattern resembles a gradual downward slope rather than a sharp separation between high-growth and low-growth markets.

Markets with broadly similar CAGRs can still present different entry conditions due to clinical infrastructure and robotic procedure readiness. The full report provides country-level analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.

Country-wise Analysis

• Endoluminal and bronchoscopy robot sales in China are anticipated to rise at 28.0% CAGR between 2026 and 2036, guided by tertiary-care expansion and domestic device development. Provincial hospital networks create practical settings for specialty-led evaluation and regional education. National Bureau of Statistics of China reported in February 2026 a total of 38,000 hospitals at year-end 2025, providing a substantial institutional base for advanced diagnostic equipment.
• Eurostat counted 99 million European Union residents aged 65 years or older at start of 2025 in its May 2026 publication, increasing pressure on oncology pathways serving older populations. Coordinated cancer networks support standardized review across university hospitals and referral centers. The market in European Union is projected to expand at 26.0% CAGR over the study period, aided by established interventional programs and cross-border clinical education.
• Established bronchoscopy installations support clinical familiarity across prominent United States thoracic centers and community referral networks. Sector in the United States is estimated to record 24.0% CAGR from 2026 to 2036, reflecting continued procedural expansion from an established installed base. American Cancer Society researchers projected in January 2024 about 234,580 new United States lung and bronchus cancer cases for 2024, sustaining need for timely tissue diagnosis across oncology programs.
• Endoluminal and bronchoscopy robot sector in Japan is forecast to grow at 23.0% CAGR during the forecast period, influenced by specialist concentration and measured capital-equipment review. Academic cancer centers offer structured settings for local evidence development and clinician education. Statistics Bureau of Japan reported in April 2025 a population of 36.24 million residents aged 65 years or older during 2024, increasing attention toward minimally invasive diagnostic access.
• Press Information Bureau announced in March 2026 approval of 297 additional district day-care cancer centres for fiscal 2025-2026, extending district-level oncology access. Metro hospital groups and public centers offer initial settings for advanced interventional platforms and specialist education. Industry in India is predicted to rise at 22.0% CAGR during the study period, aided by gradual service expansion and specialist-network development.

Who are notable companies in endoluminal and bronchoscopy robots market?

Intuitive Surgical supplies the Ion Endoluminal System for robotic bronchoscopy. Johnson & Johnson MedTech supports robotic bronchoscopy through MONARCH. Noah Medical adds Galaxy imaging-guided navigation. EndoQuest Robotics advances an investigational flexible endoluminal platform for therapeutic procedures.

Competition in endoluminal and bronchoscopy robots is anticipated to center on clinical performance and procedural support. Hospital teams are likely to compare companies through lesion access evidence and staff education prior to platform selection. Intuitive Surgical is expected to receive attention through extensive Ion deployment across trained hospital programs. Johnson & Johnson MedTech is projected to add multicenter evidence supporting MONARCH evaluation across pulmonology services. Noah Medical is estimated to support platform review through integrated imaging and real-time lesion confirmation. EndoQuest Robotics is anticipated to compete across investigational gastrointestinal procedures requiring flexible endoluminal instrument control.

• Intuitive Surgical and Johnson & Johnson MedTech are expected to gain review attention based on established robotic bronchoscopy platforms. Clinical teams are likely to assess navigation consistency and education access across complete procedural pathways.
• Noah Medical is anticipated to compete due to real-time imaging integration and compact system configuration across bronchoscopy programs. Pulmonology programs are projected to compare lesion confirmation and procedural workflow across difficult peripheral targets.
• EndoQuest Robotics is forecast to support therapeutic endoluminal evaluation across gastrointestinal applications involving flexible instrument access. Trial progress is expected to influence hospital review across academic gastroenterology and surgery programs.
• Virtuoso Surgical is likely to receive specialist interest for robotically controlled rigid endoscopic surgery. Clinical development is anticipated to influence future review across urology and other endoscopic specialties.

Competitive Benchmarking: Endoluminal & Bronchoscopy Robots Market

Company	Portfolio Depth	Clinical Match	Service Support	Service Reach
Intuitive Surgical	High	High	High	United States and selected global markets
Johnson & Johnson MedTech	High	High	High	United States and selected global markets
Noah Medical	Medium	High	Medium	United States
EndoQuest Robotics	Medium	Medium	Medium	United States development sites

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Endoluminal & Bronchoscopy Robots Market

• In March 2025, Johnson & Johnson MedTech announced United States clearance for MONARCH QUEST with AI-powered navigation and an interface supporting mobile cone-beam computed tomography. Company claims indicated increased real-time computational power of 260%, supporting more responsive navigation across difficult pulmonary targets.
• In September 2025, Virtuoso Surgical announced FDA Breakthrough Device Designation for its robotically controlled endoscopic system used in en bloc bladder lesion removal. Company information linked needle-sized robotic arms with improved instrument dexterity, strengthening future endoluminal procedure evaluation across specialist services.
• In March 2026, Noah Medical announced publication of MATCH 2 findings reporting 96.7% tool-in-lesion confirmation using embedded tomosynthesis. Company results supported Galaxy comparison for real-time targeting across peripheral pulmonary nodules requiring dependable biopsy guidance.

Key Players in Endoluminal & Bronchoscopy Robots Market

Established robotic bronchoscopy companies

• Intuitive Surgical
• Johnson & Johnson MedTech

Imaging-guided robotic bronchoscopy developer

• Noah Medical

Therapeutic endoluminal robotics developers

• EndoQuest Robotics
• Virtuoso Surgical

Endoluminal & Bronchoscopy Robots Market Report Scope

Coverage field	Report scope
Market breakdown	Endoluminal & Bronchoscopy Robots Market breakdown by platform, application, component, end user, business model, and region
Market Definition	Endoluminal and bronchoscopy robots include navigated robotic systems supporting diagnostic or therapeutic procedures through natural body openings.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East and Africa.
Countries Covered	China, Japan, USA, South Korea, Germany, and India, with the European Union included as a regional benchmark.
Key Companies Profiled	Intuitive Surgical and Johnson & Johnson MedTech with Noah Medical and EndoQuest Robotics and Virtuoso Surgical
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology using segment share and country CAGR with procedural activity and company participation and clinical evidence and service coverage

Source: Future Market Insights analysis, 2026.

Endoluminal & Bronchoscopy Robots Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Source: Future Market Insights analysis, 2026.

Endoluminal & Bronchoscopy Robots Market by Segments

Endoluminal & Bronchoscopy Robots Market segmented by Platform:

• Robotic Bronchoscopy
• Robotic GI Endoscopy
• Urology Endoluminal
• Others

Endoluminal & Bronchoscopy Robots Market segmented by Application:

• Lung Nodule Biopsy
• GI Lesion Resection
• Kidney Stone Intervention
• Others

Endoluminal & Bronchoscopy Robots Market segmented by Component:

• Systems
• Catheters & Scopes
• Services

Endoluminal & Bronchoscopy Robots Market segmented by End User:

• Academic Hospitals
• Community Hospitals
• Cancer Centers

Endoluminal & Bronchoscopy Robots Market segmented by Business Model:

• Capital Purchase
• Per-Procedure Consumables
• Lease
• Placement Programs

Endoluminal & Bronchoscopy Robots Market segmented by Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Research Sources and Bibliography

• Intuitive Surgical, Inc. (2026, April 22). Quarterly report for period ended March 31, 2026 (Form 10-Q).
• Intuitive Surgical, Inc. (2026, April 21). Intuitive announces first quarter earnings.
• Zhang, C., Xie, F., Li, R., Cui, N., Herth, F. J. F., & Sun, J. (2024). Robotic-assisted bronchoscopy for the diagnosis of peripheral pulmonary lesions: A systematic review and meta-analysis. Thoracic Cancer, 15(7), 505-512.
• World Health Organization. (2026, July 3). Cancer.
• Intuitive Surgical, Inc. (2026, January 22). Intuitive announces fourth quarter earnings.
• Johnson & Johnson MedTech. (2025, May 28). Johnson & Johnson MedTech announces new clinical data for the MONARCH platform for robotically-assisted bronchoscopy.
• Intuitive Surgical, Inc. (2026, February 3). Annual report for fiscal year ended December 31, 2025 (Form 10-K).
• American Cancer Society. (2025, November 19). Latest ACS lung cancer data: Only 1 in 5 eligible adults in USA screened for lung cancer; 62,000 lives over 5 years could be saved if all eligible screened.
• Intuitive Surgical, Inc. (2025, January 31). Annual report for fiscal year ended December 31, 2024 (Form 10-K).
• National Cancer Institute. (2025, May 6). Common cancer types.
• National Bureau of Statistics of China. (2026, February 28). Statistical communiqué of the People’s Republic of China on the 2025 national economic and social development.
• Eurostat. (2026, May 21). Demography of Europe - 2026 edition.
• Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(1), 12-49.
• Statistics Bureau of Japan. (2025, April 14). Current population estimates as of October 1, 2024.
• Press Information Bureau. (2026, March 13). Measures taken to prevent non-communicable diseases.
• Johnson & Johnson MedTech. (2025, March 12). Johnson & Johnson MedTech announces clearance of MONARCH QUEST for enhanced robotic-assisted bronchoscopy.
• Virtuoso Surgical, Inc. (2025, September 22). Virtuoso Surgical robotic system receives FDA Breakthrough Device Designation.
• Noah Medical. (2026, March 11). Respiratory Medicine publishes MATCH 2 study demonstrating reliability of real-time imaging guidance in robotic bronchoscopy.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• What segments influence demand across platform and application with component and end user and business model?
• How do pulmonology teams evaluate endoluminal and bronchoscopy robots prior to routine clinical use across hospital services?
• How do country CAGRs differ across profiled markets with distinct hospital capacity and specialist access?
• What companies compete through platform depth and clinical evidence and dependable regional service support across hospital networks?
• How are forecasts validated through hybrid bottom-up and top-down analysis using independent market indicators and company evidence?
• What evidence do hospital committees examine prior to multi-site platform expansion across clinical services and participating departments?
• How do navigation quality and lesion confirmation influence equipment selection across interventional pulmonology programs and hospital networks?
• What limits return on investment for hospitals adding endoluminal and bronchoscopy robots across specialist services?
• How do education records and specialist guidance influence hospital approval across multidisciplinary clinical teams and participating departments?
• What company capabilities improve long-term clinical confidence and continuing platform utilization across hospital networks and specialty services?